Pharmacological treatment of negative symptoms in schizophrenia

European Archives of Psychiatry and Clinical Neuroscience

Volumn 265, Issue 7, 2015, Pages 567-578

  Möller, Hans Jürgen ^a   Czobor, Pal ^b,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Antidepressants; Antipsychotics; Glutamatergic compounds; Negative symptoms; Pharmacological treatment

Indexed keywords

ANTIDEPRESSANT AGENT; DEXTRO SERINE; GLUTAMIC ACID DERIVATIVE; GLYCINE; NEUROLEPTIC AGENT; AMINO ACID RECEPTOR AFFECTING AGENT; SERINE;

CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; META ANALYSIS (TOPIC); MONOTHERAPY; MULTICENTER STUDY (TOPIC); NEGATIVE SYNDROME; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); PSYCHOLOGY; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; EXCITATORY AMINO ACID AGENTS; GLYCINE; GLYCINE AGENTS; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SERINE; TREATMENT OUTCOME;

EID: 84941937744     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-015-0596-y     Document Type: Review

References (83)

1. Andreasen NC (1990) Methods for assessing positive and negative symptoms. Mod Probl Pharmacopsychiatry 24:73–88
2. Arango C, Garibaldi G, Marder SR (2013) Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr Res 150:346–352
3. Arato M, O’Connor R, Meltzer HY (2002) A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 17:207–215
4. Blanchard JJ, Kring AM, Horan WP, Gur R (2011) Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. Schizophr Bull 37:291–299
5. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F (1995) Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166:68–72
6. Buchanan RW (2007) Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 33:1013–1022
7. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT (2007) The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 164:1593–1602
8. Buchanan RW, Panagides J, Zhao J, Phiri P, den Hollander W, Ha X, Kouassi A, Alphs L, Schooler N, Szegedi A et al (2012) Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol 32:36–45
9. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B (2001) Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 158:518–526
10. Collins AD, Dundas J (1967) A double-blind trial of amitriptyline/perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics. Br J Psychiatry 113:1425–1429
11. Committee for Proprietary Medicinal Products (CPMP) (2014) Note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia. The European Agency for the Evaluation of Medicinal Products, London. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003541.pdf. Accessed 12 Dec 2014
12. Coyle JT, Tsai G (2004) The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology 174:32–38
13. Danion JM, Rein W, Fleurot O (1999) Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 156:610–616
14. Darba J, Minoves A, Rojo E, Jimenez F, Rejas J (2011) Efficacy of second-generation-antipsychotics in the treatment of negative symptoms of schizophrenia: a meta-analysis of randomized clinical trials. Rev de Psiquiatría y Salud Mental (English Edition) 4:126–143
15. Davis JM, Chen N, Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553–564
16. Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, Stephanides M, Efferen TR, Angrist B, Peselow E et al (2004) Effects of d-cycloserine on negative symptoms in schizophrenia. Schizophr Res 71:239–248
17. European Medicines Agency (2014) Guideline on clinical investigation of medicinal products, including depot preparations in the treatment of schizophrenia. EMA/CHMP/40072/2010 Rev. 1. Committee for Medicinal Products for Human Use (CHMP), London. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/10/WC500133437.pdf. Accessed 15 Dec 2014
18. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC (2000) Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 157:826–828
19. Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, McGuire P (2014) Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull (Epub ahead of print)
20. Garcia-Portilla MP, Bobes J (2015) Psychometric evaluation of the negative syndrome of schizophrenia. Eur Arch Psychiatry Clin Neurosci (in press)
21. Goff DC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, Otto MW, Schoenfeld D, Green MF (2008) Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 106:320–327
22. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Moller HJ (2012) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13:318–378
23. Hayashi T, Yokota N, Takahashi T, Tawara Y, Nishikawa T, Yano T, Furutani M, Fujikawa T, Horiguchi J, Yamawaki S (1997) Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study. Int Clin Psychopharmacol 12:199–205
24. Hecht EM, Landy DC (2012) Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis. Schizophr Res 134:202–206
25. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC (2004) High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 55:165–171
26. Heresco-Levy U, Javitt DC (2004) Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 66:89–96
27. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M (2005) d-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 57:577–585
28. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610–617
29. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56:29–36
30. Javitt DC (2010) Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci 47:4–16
31. Javitt DC (2006) Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry 19:151–157
32. Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, Lindenmayer JP, Suckow R, Zukin SR (2001) Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol 4:385–391
33. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234–1236
34. Jockers-Scherubl MC, Bauer A, Godemann F, Reischies FM, Selig F, Schlattmann P (2005) Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. Int Clin Psychopharmacol 20:27–31
35. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796
36. Kantrowitz JT, Javitt DC (2010) N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull 83:108–121
37. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T (2003) Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 6:325–337
38. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276
39. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR (2006) The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32:214–219
40. Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR (2011) The brief negative symptom scale: psychometric properties. Schizophr Bull 37:300–305
41. Kishi T, Iwata N (2014) Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. Int J Neuropsychopharmacol 17:343–354
42. Kring AM, Gur RE, Blanchard JJ, Horan WP, Reise SP (2013) The clinical assessment interview for negative symptoms (CAINS): final development and validation. Am J Psychiatry 170:165–172
43. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE (2005) Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 62:1196–1204
44. Laughren T, Levin R (2011) Food and drug administration commentary on methodological issues in negative symptom trials. Schizophr Bull 37:255–256
45. Laughren T, Levin R (2006) Food and drug administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr Bull 32:220–222
46. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14:429–447
47. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951–962
48. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41
49. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152–163
50. Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35:51–68
51. Leucht S, Pitschel-Walz G, Engel RR, Kissling W (2002) Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159:180–190
52. Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O (1997) Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170:18–22
53. Lopez-Munoz F, Alamo C (2011) Neurobiological background for the development of new drugs in schizophrenia. Clin Neuropharmacol 34:111–126
54. Marder SR, Daniel DG, Alphs L, Awad AG, Keefe RS (2011) Methodological issues in negative symptom trials. Schizophr Bull 37:250–254
55. Moller HJ (2007) Clinical evaluation of negative symptoms in schizophrenia. Eur Psychiatry 22:380–386
56. Moller HJ (2003) Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs 17:793–823
57. Moller HJ (2004) Non-neuroleptic approaches to treating negative symptoms in schizophrenia. Eur Arch Psychiatry Clin Neurosci 254:108–116
58. Moller HJ, Jager M, Riedel M, Obermeier M, Strauss A, Bottlender R (2011) The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: assessing courses, types and time stability of diagnostic classification. Eur Psychiatry 26:231–243
59. Moller HJ, Muller H, Borison RL, Schooler NR, Chouinard G (1995) A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 245:45–49
60. Moller HJ, Riedel M, Muller N, Fischer W, Kohnen R (2004) Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. Pharmacopsychiatry 37:270–278
61. Moller HJ, van Praag HM, Aufdembrinke B, Bailey P, Barnes TR, Beck J, Bentsen H, Eich FX, Farrow L, Fleischhacker WW et al (1994) Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia. Psychopharmacology 115:221–228
62. Paillere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F (1995) Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152:130–134
63. Palmquist C (2011) Glutamatergic drugs in treatment of schizophrenia. A report on relevance. Available at: http://www.regioner.dk/~/media/Filer/Social%20og%20psykiatri/Prisopgave%202011%20Camilla%20Palmquist.ashx. Accessed 15 Dec 2014
64. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA et al (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13:1102–1107
65. Rao ML, Moller HJ (1994) Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review. Neuropsychobiology 30:160–172
66. Rein W, Turjanski S (1997) Clinical update on amisulpride in deficit schizophrenia. Int Clin Psychopharmacol 12(Suppl 2):S19–S27
67. Rummel C, Kissling W, Leucht S (2006) Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev (3):CD005581
68. Schennach R, Riedel M, Obermeier M, Spellmann I, Musil R, Jager M, Schmauss M, Laux G, Pfeiffer H, Naber D, et al. (2014) What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. Eur Arch Psychiatry Clin Neurosci 265:107–116
69. Silver H, Nassar A (1992) Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 31:698–704
70. Singh SP, Singh V, Kar N, Chan K (2010) Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry 197:174–179
71. Spina E, De Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, Di Rosa AE, Caputi AP (1994) Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 9:281–285
72. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Moeller HJ (2008) World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 100:20–38
73. Tandon R, Nasrallah HA, Keshavan MS (2010) Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophr Res 122:1–23
74. Thomas R, Baker G, Dursun S, Todd K, Dhami K, Chue J, Chue P (2014) Glycine reuptake inhibitors in the treatment of negative symptoms of schizophrenia. Bull Clin Psychopharmacol 24:195–200
75. Tollefson GD, Sanger TM (1997) Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154:466–474
76. Tsai G, Lane HY, Yang P, Chong MY, Lange N (2004) Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 55:452–456
77. Tsai G, Yang P, Chung LC, Lange N, Coyle JT (1998) d-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081–1089
78. Tsai GE, Yang P, Chang YC, Chong MY (2006) d-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 59:230–234
79. Tuominen HJ, Tiihonen J, Wahlbeck K (2006) Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev (2):CD003730
80. Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F, Dorflinger E, Wettstein JG et al (2014) Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry 71:637–646
81. Velligan DI, Alphs L, Lancaster S, Morlock R, Mintz J (2009) Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res 169:97–100
82. Vidal C, Reese C, Fischer BA, Chiapelli J, Himelhoch S (2013) Meta-analysis of efficacy of mirtazapine as an adjunctive treatment of negative symptoms in schizophrenia. Clin Schizophr Relat Psychoses. doi:10.3371/CSRP.VIRE.030813
83. Wahlbeck K, Cheine M, Essali A, Adams C (1999) Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 156:990–999